Triprolidine
Clinical data | |
---|---|
Trade names | Actidil, Myidil, Actifed (in the latter combined with pseudoephedrine and either dextromethorphan or guaifenesin) |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 4% oral |
Protein binding | 90% |
Metabolism | Hepatic (CYP2D6) |
Biological half-life | 4-6 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.006.934 |
Chemical and physical data | |
Formula | C19H22N2 |
Molar mass | 278.391 g/mol |
3D model (JSmol) | |
Melting point | 60 °C (140 °F) |
Solubility in water | 500 mg/mL (20 °C) |
| |
| |
NY (what is this?) (verify) |
Triprolidine is an over-the-counter antihistamine with anticholinergic properties.[1] It is used to combat the symptoms associated with allergies and is sometimes combined with other cold medications designed to provide general relief for flu-like symptoms.[2] Like many antihistamines, the most common side effect is drowsiness.[1] Triprolidine is a quick acting drug that can clear congestion and stop runny noses in 15–30 minutes.
References
- 1 2 Goldsmith, P.; Dowd, P. M. (1993). "The new H1 antihistamines. Treatment of urticaria and other clinical problems". Dermatologic clinics. 11 (1): 87–95. PMID 8094649.
- ↑ Williams, B. O.; Liao, S. H.; Lai, A. A.; Arnold, J. D.; Perkins, J. G.; Blum, M. R.; Findlay, J. W. (1984). "Bioavailability of pseudoephedrine and triprolidine from combination and single-ingredient products". Clinical pharmacy. 3 (6): 638–643. PMID 6509877.
Aminoalkyl ethers |
|
---|---|
Substituted alkylamines | |
Substituted ethylenediamines |
|
Phenothiazine derivatives | |
Piperazine derivatives | |
Others for systemic use |
|
For topical use |
Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Others |
|
H1 |
|
---|---|
H2 |
|
H3 |
|
H4 |
|
See also: Receptor/signaling modulators • Monoamine metabolism modulators • Monoamine reuptake and release modulators |
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.